|
LEXARIA BIOSCIENCE CORP. (LEXX) Avaliação DCF
CA | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Lexaria Bioscience Corp. (LEXX) Bundle
Seja você um investidor ou analista, esta calculadora DCF (Lexx) é o seu recurso preferido para uma avaliação precisa. Equipado com dados reais da Lexaria Bioscience Corp., você pode ajustar as previsões e observar os efeitos em tempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .4 | .7 | .3 | .2 | .5 | .6 | .8 | 1.0 | 1.2 | 1.6 |
| Revenue Growth, % | 0 | 87.95 | -64.66 | -11.43 | 105.24 | 27.96 | 27.96 | 27.96 | 27.96 | 27.96 |
| EBITDA | -4.0 | -5.6 | -6.5 | -6.4 | -5.7 | -.6 | -.8 | -1.0 | -1.2 | -1.6 |
| EBITDA, % | -1040.9 | -771.39 | -2551.45 | -2824.23 | -1222.75 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .1 | .1 | .1 | .1 | .1 | .2 | .3 | .4 | .5 | .6 |
| Depreciation, % | 37.99 | 20.42 | 57.52 | 64.28 | 16.4 | 39.32 | 39.32 | 39.32 | 39.32 | 39.32 |
| EBIT | -4.1 | -5.7 | -6.7 | -6.5 | -5.8 | -.6 | -.8 | -1.0 | -1.2 | -1.6 |
| EBIT, % | -1078.89 | -791.81 | -2608.97 | -2888.5 | -1239.16 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 1.3 | 11.8 | 6.2 | 1.5 | 6.6 | .6 | .8 | 1.0 | 1.2 | 1.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .3 | .3 | .2 | .2 | .2 | .4 | .5 | .6 | .8 | 1.0 |
| Account Receivables, % | 81.64 | 47.38 | 79.01 | 77.47 | 33.27 | 63.75 | 63.75 | 63.75 | 63.75 | 63.75 |
| Inventories | .1 | .0 | .0 | .0 | .0 | .1 | .1 | .1 | .1 | .2 |
| Inventories, % | 30.39 | 4.1 | 15.04 | 0 | 0 | 9.91 | 9.91 | 9.91 | 9.91 | 9.91 |
| Accounts Payable | .0 | .1 | .0 | .2 | 1.1 | .3 | .3 | .4 | .6 | .7 |
| Accounts Payable, % | 11.72 | 8.29 | 10.12 | 99.48 | 227.86 | 45.92 | 45.92 | 45.92 | 45.92 | 45.92 |
| Capital Expenditure | .0 | -.1 | -.1 | -.2 | .0 | -.2 | -.2 | -.3 | -.4 | -.5 |
| Capital Expenditure, % | -8.75 | -11 | -51.47 | -74.98 | -9.26 | -31.09 | -31.09 | -31.09 | -31.09 | -31.09 |
| Tax Rate, % | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 |
| EBITAT | -4.1 | -3.4 | -6.6 | -6.5 | -5.7 | -.5 | -.7 | -.9 | -1.1 | -1.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4.4 | -3.3 | -6.4 | -6.2 | -4.9 | -1.6 | -.7 | -.9 | -1.1 | -1.4 |
| WACC, % | 9.07 | 9.06 | 9.07 | 9.07 | 9.07 | 9.07 | 9.07 | 9.07 | 9.07 | 9.07 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -20 | |||||||||
| Present Terminal Value | -13 | |||||||||
| Enterprise Value | -18 | |||||||||
| Net Debt | -6 | |||||||||
| Equity Value | -11 | |||||||||
| Diluted Shares Outstanding, MM | 12 | |||||||||
| Equity Value Per Share | -0.91 |
What You Will Get
- Authentic Lexaria Data: Preloaded financials – covering everything from revenue to EBIT – based on actual and projected figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Updates: Automatic recalculations to assess the impact of changes on Lexaria’s fair value.
- Flexible Excel Template: Designed for quick edits, scenario analysis, and detailed forecasts.
- Efficient and Precise: Bypass the hassle of building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Lexaria Bioscience Corp. (LEXX).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to LEXX.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates as needed for Lexaria.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Lexaria Bioscience Corp. (LEXX).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- 1. Download the Template: Obtain and open the Excel file containing Lexaria Bioscience Corp.'s (LEXX) preloaded data.
- 2. Modify Key Inputs: Adjust critical assumptions such as growth projections, WACC, and capital investments.
- 3. Analyze Results in Real-Time: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand a range of valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation analyses to enhance your decision-making process.
Why Choose Lexaria Bioscience Corp. (LEXX)?
- Innovation: Pioneering advancements in cannabinoid delivery technology.
- Research-Driven: Backed by extensive scientific studies and clinical trials.
- Market Potential: Positioned in a rapidly growing industry with significant opportunities.
- Experienced Leadership: Led by a team with deep expertise in biotech and pharmaceuticals.
- Commitment to Quality: Focused on high standards in product development and manufacturing.
Who Should Use This Product?
- Investors: Evaluate Lexaria Bioscience Corp.'s (LEXX) market potential before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts for Lexaria.
- Startup Founders: Understand the valuation strategies of innovative biotech companies like Lexaria.
- Consultants: Create comprehensive valuation reports tailored for clients interested in Lexaria Bioscience Corp. (LEXX).
- Students and Educators: Utilize current data to explore and teach valuation principles in the biotech sector.
What the Lexaria Bioscience Template Contains
- Preloaded LEXX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.